Alexandria Real Estate (ARE) Stock: Dividend Cut, FFO, Debt (2026)

Is Alexandria Real Estate Equities still ARE, and what has been filed?

Yes. The company is Alexandria Real Estate Equities, Inc., a Maryland corporation based in Pasadena, California, listed on the New York Stock Exchange under ARE and a member of the S&P 500. It describes itself as a life science REIT that owns, operates and develops laboratory and office space in clusters such as Greater Boston, San Diego and the San Francisco Bay Area. There has been no merger, ticker change or name change, so searches for “alexandria real estate stock”, “ARE stock” and “Alexandria Real Estate Equities” are the same company.

The latest 10-Q on EDGAR is for the quarter ended June 30, 2026, filed August 3, 2026 together with the Q2 earnings release. The latest 8-K is dated September 24, 2026 and reports that a new $5 billion revolving credit agreement became effective. The Q3 2026 10-Q is not filed as of October 19, 2026. In an August 25, 2026 press release the company said it will release third-quarter results after the market closes on Monday, October 26, 2026 and hold its call on Tuesday, October 27 at 2:00 p.m. Eastern. In each of the last four reports the earnings release and the 10-Q (or 10-K) were filed the same day (October 27, 2025; January 26, 2026; April 27, 2026; August 3, 2026), so the 10-Q should appear on or about those dates (our reading of the pattern, not a company statement). Everything below is as of June 30, 2026 unless it says otherwise. We found no EDGAR filing announcing a third-quarter dividend declaration; the company's earnings supplement reports declared dividends.

The dividend against FFO, quarter by quarter

Alexandria's own yardstick is funds from operations per share, diluted, as adjusted: Nareit FFO with items such as unrealized gains and losses on non-real estate investments, investment impairments and gains or losses on early extinguishment of debt taken out. It is a non-GAAP measure defined by the company. The dividend payout ratio in the table is the company's: dividends on common stock divided by that measure.

Four readings the quote pages do not make.

The payout fell because the dividend was cut. The company declared $0.72 for the fourth quarter of 2025 in December 2025, “representing a 45% reduction from the quarterly dividend declared of $1.32 for 3Q25,” in the words of the January 26, 2026 release. At $1.32 on the Q2 2026 FFO of $1.73 the payout would have been 76% (our arithmetic). Full-year 2025 dividends declared were $4.68 against $9.01 of FFO as adjusted, 51.9% (our arithmetic); 2024 was $5.19 against $9.47, 54.8% (our arithmetic).

FFO per share has fallen in five of the last six quarters. From $2.39 in Q4 2024 to $1.73 in Q2 2026 is a 27.6% drop (our arithmetic). The step from $2.16 to $1.73 between Q4 2025 and Q1 2026 is the largest. In dollars, FFO as adjusted was $296.1 million in Q2 2026 against $396.4 million in Q2 2025, and total revenues were $662.8 million against $762.0 million, down 13.0% (our arithmetic). The release says the 2026 guidance assumes a $25 million to $30 million reduction in FFO from potential tenant wind-downs, of which about $14 million was recognized in the first half, including about $8 million in Q2.

GAAP earnings and FFO diverge sharply. The company reported a net loss of $8.44 per share for 2025, driven by impairments of real estate: $1,717.2 million in Q4 2025 and $222.5 million in Q2 2026 on the income statement. First-half 2026 net income of $1.68 per share was entirely the $366.4 million gain on early extinguishment of debt from the February 2026 bond tender (the company bought back $1.33 billion of notes at a 28 percent discount for $952.2 million); the second quarter alone was a loss of $0.43. FFO as adjusted removes that gain, which is why it is $1.73 in both quarters.

The company says the quoted yield is 5.4%. Its Q2 release states: “Dividend yield of 5.4% as of June 30, 2026 and dividend payout ratio of 42% for the three months ended June 30, 2026.” That uses the June 30 closing price of $52.85, not today's price. The closing price was $83.34 at September 30, 2025 and $48.94 at December 31, 2025 (a 41.3% fall in one quarter, our arithmetic), and we do not have a current quote from a filing.

What the dividend is paid from

The company reports “net cash provided by operating activities, as adjusted,” which already subtracts common dividends and distributions to noncontrolling interests. For the first half of 2026 it was $340.9 million (first half of 2025: $290.5 million). Common dividends paid were $247.6 million in the half against $457.2 million a year earlier, down 45.8% (our arithmetic). The retained cash is meant for construction: 2026 guidance has $1.75 billion of construction spending at the midpoint, against $525 million of retained operating cash flow. The company's Q2 release sets out the gap: $2.9 billion of dispositions, sales of partial interests and other capital sources, of which $1.675 billion goes to reducing debt. A dividend that is 42% of FFO therefore sits inside a plan in which most of the funding comes from asset sales, not from retained earnings.

2026 guidance: the midpoint has not moved, the range has

The company says that on August 3 it kept the midpoint because later asset sales (about six weeks later than assumed, September instead of August) are expected to offset higher interest expense and lower capitalized interest. Interest expense guidance went up $20 million to a range of $260 million to $300 million; first-half interest expense was $128.9 million, so the midpoint implies about $151 million in the second half, $75.5 million a quarter against $64.3 million in Q2 2026 (our arithmetic). Capitalized interest, which keeps interest out of the income statement while projects are under construction, is guided to $220 million to $260 million, and the company expects less of it in the fourth quarter as projects reach milestone dates or are paused.

Other 2026 guidance lines (August 3): operating occupancy at December 31, 2026 of 86.2% to 87.8%; same-property NOI down 10.5% to 8.5%; renewal rent changes of minus 9.0% to minus 1.0% (cash basis minus 15.0% to minus 7.0%); general and administrative expense of $134 million to $154 million. The company gave a first view of 2027 construction spending of $1.15 billion to $1.65 billion, $100 million to $600 million below the 2026 midpoint, and said it will give 2027 guidance at its Investor Day on December 2, 2026.

What changed in the latest quarter

Operating occupancy slipped 0.8 points from March 31, 2026 (87.7%): the release attributes 0.8 points to key lease expirations with expected downtime and 0.4 points to reclassifying 159,947 square feet at 3000 Minuteman Road in Greater Boston from redevelopment to operating, offset by 0.4 points of lease commencements. That space was leased to an advanced-technology tenant, which lets the company pivot from laboratory to a lower-cost use and cut the project's budget by about $80 million, at lower rents than first underwritten. Signed leases not yet occupied total 1.4 million square feet, about $69 million of annual rent, with a weighted-average start of about November 2026 and 64% expected occupied by December 31.

Leasing volume was 1,038,917 square feet in Q2 2026 against 647,356 in Q1. Advanced-technology tenants were 29.2% of Q2 volume, and the company notes that this space “typically generates lower rental rates” than laboratory space (its words in footnote 2 of the leasing table). In Q2 the company placed one development, 426,927 square feet for Bristol Myers Squibb on a 15-year lease, into service. Q2 impairments were mostly on assets held for sale: a land parcel in Sorrento Mesa, an operating property in Canada, five Sorrento Valley properties and a vacant Cambridge office building. The company reports 99.9% collection of Q2 rents as of August 3, 2026.

Who pays the rent

Quality is high on paper: 88% of top-20 rent is from investment-grade or publicly traded large-cap tenants, 57% of all rent, and the weighted remaining term is 10.0 years for the top 20 and 7.7 years for all tenants. The less comfortable list is the one the company itself flags. The AstraZeneca lease at Alexandria Center for Life Science in Waltham ($27.0 million of rent, 232,902 square feet, expiring in the first quarter of 2027) is one the company says it does not expect to renew. The Novartis lease at 100 Technology Square in Cambridge ($21.0 million, 255,441 square feet, expiring March 2028) is the same. Bristol Myers Squibb will leave 317,385 square feet in four properties ($24.0 million, April 2027) for its new building at 4135 Campus Point Court, and the company has early discussions on 190,085 square feet of the vacated space.

Eikon Therapeutics (2.1%), Moderna (3.9%) and Vaxcyte, Altos Labs and Charles River (about 1.0% each) have no credit rating shown in the company's table.

Markets

Three markets are 73% of annual rental revenue (our arithmetic) and they are also the three where occupancy fell most. The company says 80% of rent is from its Megacampus properties. At the whole-portfolio level, annual rental revenue was $1.85 billion, or $60.45 per occupied square foot.

Lease expirations

Through 2028 the buckets add to 22.4% of rent (our arithmetic). Inside them the company has singled out “key lease expirations with expected downtime”: 451,450 square feet and $18.1 million of rent in 2026 (average expiry August 2026) and 1,377,960 square feet and $100.5 million in 2027 (average expiry March 2027), each with an expected 12 to 24 months of downtime. Together that is $118.6 million, 6.4% of June 30 annual rent (our arithmetic). Of the $100.5 million in 2027, the company notes the Bristol Myers Squibb relocation and the AstraZeneca Waltham lease described above. The company says it will keep adding capital sources beyond 2026 for this reason: it cites 2027 expirations with downtime, construction to complete projects that are 71% leased, and capital expenditure to lease vacant space.

Debt: $12.8 billion, a short list of near maturities, and a new 7.25% layer

At June 30, 2026 total debt and preferred stock was $12,812.9 million (there is no preferred stock outstanding, per the 10-Q): $10,818.4 million of unsecured senior notes at 4.04% and $1,994.5 million of commercial paper at 4.27%, with nothing drawn on the $5 billion revolver. The weighted-average rate was 4.08% and the weighted-average remaining term 9.7 years, which the company says is the longest among S&P 500 REITs; using the commercial paper's own maturities it is 9.2 years. Total debt was 31% of gross assets, and liquidity was $3.60 billion.

Three points.

• Near-term bond maturities are small; short-term debt is the real exposure. Notes due before 2029 total $775.0 million, 6.0% of principal (our arithmetic; the company says “only 6%”). But $1.99 billion is commercial paper, with an average maturity of 15 days in the first half, backed by the revolver. On September 24, 2026 the new fourth amended credit agreement took effect: $5 billion, maturing January 22, 2032 (with two six-month extension options), at a margin of 0.725% over the floating rate, down from 0.835%. The signed agreement had been held in escrow since July 9, 2026 until its conditions were met.
• New money costs more than the old. The company repaid $350 million of 3.80% notes in April 2026 with commercial paper, issued $750 million of 5.25% notes due 2036 in February to fund the tender, and on August 21 issued $1.0 billion of 7.250% Series A junior subordinated notes due 2057. The coupon is fixed to February 15, 2032, then resets to the five-year Treasury rate plus 2.889% with a floor at 7.250%. The company may defer interest, and during a deferral it may not pay dividends other than a “Permitted REIT Status Dividend.” The proceeds go to general corporate purposes, including reducing commercial paper. The prospectus states the notes are junior to all senior debt. We have no filing yet on how the proceeds were used; the Q3 report will show.
• Covenants have room. At June 30, 2026 the company showed total debt to total assets of 32% against a 60% limit on its senior notes, and consolidated EBITDA to interest expense of 7.4 times against a 1.5 times minimum. The tighter measure is leverage as the rating agencies and the company see it: 7.0 times annualized (6.4 times trailing twelve months) against a goal of the “mid-5x range.”

Where the money to get to 5.6-6.2 times comes from

Completed plus pending is $1.33 billion, 46% of the midpoint; the company adds $1.10 billion “in process” and $471 million of alternatives. At June 30 the company had 23 operating properties and land held for sale, and the 10-Q says it is committed to dispose of held-for-sale assets with a book value of $555.8 million in 2026. The company has also sold $1.81 billion in 2025, and non-income-producing assets are 16% of gross assets with a target of 11% to 16% by Q4 2026. The company states: “We do not anticipate the issuance of any common equity during the year ending December 31, 2026.” At June 30 the $500 million repurchase program authorized in December 2025 had not been used, and $1.47 billion remained on the at-the-market program. Shares outstanding were 170.7 million, up from 170.1 million a year earlier. The company also holds $1.69 billion of non-real estate investments, mostly stakes in life science companies, which produced $133.2 million of investment income in Q2, of which $131.9 million was unrealized gains that FFO as adjusted excludes.

The company's own statement on risk to this plan is in the release: “We expect improvement in our quarter-annualized net debt and preferred stock to Adjusted EBITDA ratio in 2H26 as we complete dispositions, sales of partial interests, and other capital sources.” If the sales slip, leverage stays above target; the company has already moved its assumed completion date from August to September.

ARE against a non-traded vehicle

Readers of our pages on office REIT dividends, occupancy and debt and BXP's dividend and office portfolio often want the listed benchmark for a niche property type. ARE is a hard one because it shows exactly what a weak-demand year does to a distribution. For how listed and non-traded REITs differ in exit and pricing, see our comparison.

The comparison does not say listed is better. A listed REIT's price fell 41.3% in a quarter (September 30 to December 31, 2025, our arithmetic) while a non-traded vehicle's appraised value would have moved less and later. What the listed company shows, at least, is the full list in the left column every quarter.

What a holder or reader can do with this

This page is analysis of public documents, not investment, legal or tax advice. What the filings let you check yourself:

• Read the payout with the dividend cut in mind. 42% of FFO is the company's figure for the latest quarter; the 76% it would be at the old $1.32 shows why the board acted. A change in the $0.72 is a board decision; the 10-Q does not promise it.
• Track three numbers each quarter: FFO as adjusted per share (the guide is $1.40 to $1.50 for Q4), operating occupancy (86.2% to 87.8% guided for year-end) and net debt plus preferred over Adjusted EBITDA (7.0x against 5.6 to 6.2x).
• Watch five dated items: the Q3 results and 10-Q (release October 26, call October 27); the Q3 dividend declaration; what happened to the $1.16 billion of pending sales; the AstraZeneca Waltham and Bristol Myers Squibb expirations in early 2027; and the December 2, 2026 Investor Day, where 2027 guidance is due.
• Size the position. ARE is one company in one property type; three markets are 73% of its rent. A shareholder who bought before 2025 has seen a 45% cut and a share price that fell from $83.34 to $52.85 between September 30, 2025 and June 30, 2026 (our arithmetic: 36.6%).

FAQ

All figures are from Alexandria Real Estate Equities, Inc. (SEC CIK 1035443) filings read on EDGAR on October 19, 2026: Form 10-K for 2025 (accession 0001035443-26-000013); Forms 10-Q for the quarters ended September 30, 2025 (0001035443-25-000198) and June 30, 2026 (0001035443-26-000066, filed August 3, 2026); earnings releases and supplemental information attached to Forms 8-K for Q3 2025 (0001035443-25-000199), Q4 2025 (0001035443-26-000014), Q1 2026 (0001035443-26-000045) and Q2 2026 (0001035443-26-000067); the Form 8-K of October 29, 2025 (0001035443-25-000202); the Form 8-K of December 3, 2025 with the Investor Day presentation and 2026 guidance (0001035443-25-000211); the December 8, 2025 repurchase 8-K (0001104659-25-119298); the Forms 8-K of July 9, 2026 (0001035443-26-000058), August 14, 2026 (0001104659-26-097337, pricing release dated August 12), August 21, 2026 (0001104659-26-099706) and September 24, 2026 (0001035443-26-000069); the preliminary prospectus supplement of August 10, 2026 (0001104659-26-093108); and the company's August 25, 2026 press release on the Q3 call, as published by PR Newswire. FFO, FFO as adjusted, Adjusted EBITDA, net operating income and annual rental revenue are the company's non-GAAP definitions. Payout ratios and yields in the table are the company's; other percentages, sums and sensitivities are our arithmetic from those rows. Share prices are the June 30, September 30 and December 31 closes printed in the company's supplemental information and are not current. This is analysis of public documents, not investment, legal or tax advice.